FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Emerg Microbes Infect / Env diversity-dependent protection of the attenuated equine ...
Emerging microbes & infections2020; 9(1); 1309-1320; doi: 10.1080/22221751.2020.1773323

Env diversity-dependent protection of the attenuated equine infectious anaemia virus vaccine.

Abstract: Lentiviruses harbour high genetic variability for efficient evasion from host immunity. An attenuated equine infectious anaemia (EIA) vaccine was developed decades ago in China and presented remarkably robust protection against EIA. The vaccine was recently proven to have high genomic diversity, particular in . However, how and to what extent the high diversity relates to immune protection remains unclear. In this study, we compared immune protections and responses of three groups of horses stimulated by the high-diversity vaccine EIAV_HD, a single molecular clone of the vaccine EIAV_LD with low diversity, as well as a constructed vaccine strain EIAV_MD with moderate diversity. The disparity of virus-host interactions between three diversity-varied groups (5 horses in each group) was evaluated using clinical manifestation, pathological scores, and -specific antibody. We found the highest titres of antibodies (Abs) or neutralizing Abs (nAbs) in the EIAV_HD group, followed by the EIAV_MD group, and the lowest titres in the EIAV_LD group (<0.05). The occurrence of disease/death was different between EIAV_HD group (1/0), EIAV_MD (2/2), and EIAV_LD group (4/2). A similar diversity-related linear relationship was observed in the clinical manifestations and pathological changes. This diversity-dependent disparity in changes between the three groups was more distinct after immunosuppression, suggesting that diversity plays an important role in protection under low host immunocompetence. In summary, inoculation with vaccines with higher genetic diversity could present broader and more efficient protection. Our findings strongly suggest that an abundance of Env antigens are required for efficient protection against lentiviruses.
Get Full Text
Publication Date: 2020-06-12 PubMed ID: 32525460PubMed Central: PMC7473056DOI: 10.1080/22221751.2020.1773323Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study presents the research conducted on the relationship between genetic diversity and immune protection, specifically in the context of the equine infectious anaemia (EIA) vaccine. It was observed that vaccines with higher genetic diversity offered a broader and more effective protection, strengthening the idea that abundant Env antigens are needed for efficient protection against lentiviruses.

Study Design and Methodology

  • The researchers developed a study wherein they compared the immune protections and responses of three groups of horses. Each group was stimulated by a variant of the EIA vaccine – one with high genetic diversity (EIAV_HD), another one from a single molecular clone of the vaccine with low genetic diversity (EIAV_LD), and a third strain constructed with moderate genetic diversity (EIAV_MD).
  • Each group consisted of five horses and evaluations were based on clinical manifestation, pathological scores, and -specific antibody.

Findings and Observations

  • The results indicated that the EIAV_HD group presented the highest concentrations of antibodies or neutralising antibodies, succeeded by the EIAV_MD group, and with the lowest concentrations in the EIAV_LD group. The occurrence of illness or death was also different across groups (1/0 in EIAV_HD group, 2/2 in EIAV_MD, and 4/2 in EIAV_LD).
  • Consistent diversity-related relationships were noticed in the manifestation of clinical symptoms and pathological alterations across the three groups.
  • This diversity-dependent disparity became more pronounced following immunosuppression, indicating that genetic diversity plays a part in protection, particularly when host immunocompetence is low.

Conclusions

  • The research concluded that vaccines with a greater degree of genetic diversity could provide broader and more effective protection against these types of diseases.
  • The findings strongly suggest that an ample amount of Env antigens are necessary for efficient protection against lentiviruses like EIA.

In a broader context, these findings emphasise the relevance of understanding and enhancing genetic diversity in the development and effectiveness of vaccines against not just EIA, but potentially other lentiviruses as well.

Cite This Article

APA
Lin Y, Wang XF, Wang Y, Du C, Ren H, Liu C, Zhu D, Chen J, Na L, Liu D, Yang Z, Wang X. (2020). Env diversity-dependent protection of the attenuated equine infectious anaemia virus vaccine. Emerg Microbes Infect, 9(1), 1309-1320. https://doi.org/10.1080/22221751.2020.1773323

Publication

Emerging microbes & infections
ISSN: 2222-1751
NlmUniqueID: 101594885
Country: United States
Language: English
Volume: 9
Issue: 1
Pages: 1309-1320

Researcher Affiliations

Lin, Yuezhi
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Wang, Xue-Feng
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
  • Shanghai Key Laboratory of Veterinary Biotechnology, Shanghai, People's Republic of China.
Wang, Yuhong
  • Department of Geriatrics and Gerontology, First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Du, Cheng
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Ren, Huiling
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Liu, Cong
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Zhu, Dantong
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Chen, Jie
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Na, Lei
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Liu, Diqiu
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Yang, Zhibiao
  • Shanghai Key Laboratory of Veterinary Biotechnology, Shanghai, People's Republic of China.
Wang, Xiaojun
  • State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.

MeSH Terms

  • Animals
  • Antibodies, Neutralizing / metabolism
  • Antibodies, Viral / metabolism
  • Equine Infectious Anemia / immunology
  • Equine Infectious Anemia / prevention & control
  • Gene Products, env / genetics
  • Gene Products, env / immunology
  • High-Throughput Nucleotide Sequencing
  • Horses
  • Infectious Anemia Virus, Equine / physiology
  • Polymorphism, Single Nucleotide
  • Vaccines, Attenuated
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology
  • Viral Vaccines / pharmacology
  • Virus Replication / drug effects

Conflict of Interest Statement

No potential conflict of interest was reported by the author(s).

References

This article includes 43 references
  1. Lin YZ, Shen RX, Zhu ZY, Deng XL, Cao XZ, Wang XF, Ma J, Jiang CG, Zhao LP, Lv XL, Shao YM, Zhou JH. An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.. Antiviral Res 2011 Nov;92(2):292-304.
    pubmed: 21893100doi: 10.1016/j.antiviral.2011.08.016google scholar: lookup
  2. Wang XF, Liu Q, Wang YH, Wang S, Chen J, Lin YZ, Ma J, Zhou JH, Wang X. Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies In Vitro and In Vivo.. J Virol 2018 Apr 15;92(8).
    pmc: PMC5874411pubmed: 29386282doi: 10.1128/JVI.02150-17google scholar: lookup
  3. Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Wang F, Shen R, Kong X, Zhou J. Genomic comparison between attenuated Chinese equine infectious anemia virus vaccine strains and their parental virulent strains.. Arch Virol 2011 Feb;156(2):353-7.
    pubmed: 21136127doi: 10.1007/s00705-010-0877-8google scholar: lookup
  4. Wang XF, Lin YZ, Li Q, Liu Q, Zhao WW, Du C, Chen J, Wang X, Zhou JH. Genetic Evolution during the development of an attenuated EIAV vaccine.. Retrovirology 2016 Feb 3;13:9.
    pmc: PMC4738788pubmed: 26842878doi: 10.1186/s12977-016-0240-6google scholar: lookup
  5. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1.. Nature 2003 Mar 20;422(6929):307-12.
    pubmed: 12646921doi: 10.1038/nature01470google scholar: lookup
  6. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 2008 Jan 21;205(1):7-12.
    pmc: PMC2234358pubmed: 18195078doi: 10.1084/jem.20072681google scholar: lookup
  7. Chen Z. Monkey Models and HIV Vaccine Research.. Adv Exp Med Biol 2018;1075:97-124.
    pubmed: 30030791doi: 10.1007/978-981-13-0484-2_5google scholar: lookup
  8. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, Issel CJ, Montelaro RC. Envelope variation as a primary determinant of lentiviral vaccine efficacy.. Proc Natl Acad Sci U S A 2007 Sep 18;104(38):15105-10.
    pmc: PMC1986620pubmed: 17846425doi: 10.1073/pnas.0706449104google scholar: lookup
  9. Bell SM, Bedford T. Modern-day SIV viral diversity generated by extensive recombination and cross-species transmission.. PLoS Pathog 2017 Jul;13(7):e1006466.
    pmc: PMC5510905pubmed: 28672035doi: 10.1371/journal.ppat.1006466google scholar: lookup
  10. Liu C, Wang XF, Wang Y, Chen J, Zhong Z, Lin Y, Wang X. Characterization of EIAV env Quasispecies during Long-Term Passage In Vitro: Gradual Loss of Pathogenicity.. Viruses 2019 Apr 24;11(4).
    pmc: PMC6520696pubmed: 31022927doi: 10.3390/v11040380google scholar: lookup
  11. Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, Montelaro RC. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.. J Virol 2008 Apr;82(8):4052-63.
    pmc: PMC2292999pubmed: 18234792doi: 10.1128/JVI.02028-07google scholar: lookup
  12. Moore PL. The Neutralizing Antibody Response to the HIV-1 Env Protein.. Curr HIV Res 2018;16(1):21-28.
    pmc: PMC6234226pubmed: 29173180doi: 10.2174/1570162X15666171124122044google scholar: lookup
  13. Steinhardt JJ, Guenaga J, Turner HL, McKee K, Louder MK, O'Dell S, Chiang CI, Lei L, Galkin A, Andrianov AK, A Doria-Rose N, Bailer RT, Ward AB, Mascola JR, Li Y. Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.. Nat Commun 2018 Feb 28;9(1):877.
    pmc: PMC5830440pubmed: 29491415doi: 10.1038/s41467-018-03335-4google scholar: lookup
  14. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, Sambor A, Chakrabarti BK, Huang Y, Bailer R, Koup RA, Mascola JR, Nabel GJ, Letvin NL. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.. J Virol 2005 Mar;79(5):2956-63.
    pmc: PMC548456pubmed: 15709015doi: 10.1128/JVI.79.5.2956-2963.2005google scholar: lookup
  15. Sadanand S, Suscovich TJ, Alter G. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.. Annu Rev Med 2016;67:185-200.
    pubmed: 26565674doi: 10.1146/annurev-med-091014-090749google scholar: lookup
  16. Zhu C, Dukhovlinova E, Council O, Ping L, Faison EM, Prabhu SS, Potter EL, Upton SL, Yin G, Fay JM, Kincer LP, Spielvogel E, Campbell SL, Benhabbour SR, Ke H, Swanstrom R, Dokholyan NV. Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies.. Nat Commun 2019 Feb 27;10(1):948.
    pmc: PMC6393580pubmed: 30814513doi: 10.1038/s41467-019-08876-wgoogle scholar: lookup
  17. Wang XF, Bai B, Lin Y, Qi T, Du C, Song M, Wang X. High-Efficiency Rescue of Equine Infectious Anemia Virus from a CMV-Driven Infectious Clone.. Virol Sin 2019 Dec;34(6):725-728.
    pmc: PMC6888787pubmed: 31376080doi: 10.1007/s12250-019-00153-wgoogle scholar: lookup
  18. Braun MJ, Clements JE, Gonda MA. The visna virus genome: evidence for a hypervariable site in the env gene and sequence homology among lentivirus envelope proteins.. J Virol 1987 Dec;61(12):4046-54.
    pmc: PMC256031pubmed: 2824836doi: 10.1128/JVI.61.12.4046-4054.1987google scholar: lookup
  19. Lin YZ, Cao XZ, Li L, Li L, Jiang CG, Wang XF, Ma J, Zhou JH. The pathogenic and vaccine strains of equine infectious anemia virus differentially induce cytokine and chemokine expression and apoptosis in macrophages.. Virus Res 2011 Sep;160(1-2):274-82.
    pubmed: 21782860doi: 10.1016/j.virusres.2011.06.028google scholar: lookup
  20. Ma J, Shi N, Jiang CG, Lin YZ, Wang XF, Wang S, Lv XL, Zhao LP, Shao YM, Kong XG, Zhou JH, Shen RX. A proviral derivative from a reference attenuated EIAV vaccine strain failed to elicit protective immunity.. Virology 2011 Feb 5;410(1):96-106.
    pubmed: 21094511doi: 10.1016/j.virol.2010.10.032google scholar: lookup
  21. Mann JK, Ndung'u T. HIV-1 vaccine immunogen design strategies.. Virol J 2015 Jan 24;12:3.
    pmc: PMC4318220pubmed: 25616599doi: 10.1186/s12985-014-0221-0google scholar: lookup
  22. Korber B, Hraber P, Wagh K, Hahn BH. Polyvalent vaccine approaches to combat HIV-1 diversity.. Immunol Rev 2017 Jan;275(1):230-244.
    pmc: PMC5362114pubmed: 28133800doi: 10.1111/imr.12516google scholar: lookup
  23. Hurwitz JL, Bonsignori M. Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.. Viral Immunol 2018 Mar;31(2):124-132.
    pmc: PMC5915263pubmed: 29315059doi: 10.1089/vim.2017.0144google scholar: lookup
  24. Badamchi-Zadeh A, McKay PF, Korber BT, Barinaga G, Walters AA, Nunes A, Gomes JP, Follmann F, Tregoning JS, Shattock RJ. A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance.. Front Immunol 2016;7:162.
    pmc: PMC4848310pubmed: 27199987doi: 10.3389/fimmu.2016.00162google scholar: lookup
  25. Kamlangdee A, Kingstad-Bakke B, Osorio JE. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.. J Virol 2016 Aug 1;90(15):6771-6783.
    pmc: PMC4944288pubmed: 27194759doi: 10.1128/JVI.00730-16google scholar: lookup
  26. Escolano A, Dosenovic P, Nussenzweig MC. Progress toward active or passive HIV-1 vaccination.. J Exp Med 2017 Jan;214(1):3-16.
    pmc: PMC5206506pubmed: 28003309doi: 10.1084/jem.20161765google scholar: lookup
  27. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.. J Exp Med 2013 Apr 8;210(4):655-63.
    pmc: PMC3620356pubmed: 23530120doi: 10.1084/jem.20122824google scholar: lookup
  28. Sliepen K, Sanders RW. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.. Expert Rev Vaccines 2016;15(3):349-65.
    pubmed: 26654478doi: 10.1586/14760584.2016.1129905google scholar: lookup
  29. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.. Virology 2006 Jun 20;350(1):34-47.
    pubmed: 16616287doi: 10.1016/j.virol.2006.02.032google scholar: lookup
  30. Abdul-Jawad S, Ondondo B, van Hateren A, Gardner A, Elliott T, Korber B, Hanke T. Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.. Mol Ther 2016 Feb;24(2):375-384.
    pmc: PMC4817818pubmed: 26581160doi: 10.1038/mt.2015.210google scholar: lookup
  31. Cai H, Zhang R, Orwenyo J, Giddens J, Yang Q, LaBranche CC, Montefiori DC, Wang LX. Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine.. ACS Cent Sci 2018 May 23;4(5):582-589.
    pmc: PMC5968512pubmed: 29806004doi: 10.1021/acscentsci.8b00060google scholar: lookup
  32. Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M, Chen X, Choi CW, Dandey VP, Doria-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.. Nat Med 2018 Jun;24(6):857-867.
    pmc: PMC6358635pubmed: 29867235doi: 10.1038/s41591-018-0042-6google scholar: lookup
  33. Xu F, Hong M, Ulmer JB. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella.. Vaccine 2003 Jan 30;21(7-8):644-8.
    pubmed: 12531333doi: 10.1016/s0264-410x(02)00573-xgoogle scholar: lookup
  34. Jiang WZ, Jin NY, Li ZJ, Zhang LS. [Study on the immunogenicity of HIV-1 gag vaccine].. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2004 May;20(3):272-3.
    pubmed: 15193215
  35. Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM, Ambrozak DR, Tomaras G, Roederer M, Kilby JM, Tartaglia J, Belshe R, Gao F, Douek DC, Weinhold KJ, Koup RA, Goepfert P, Ferrari G. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.. Proc Natl Acad Sci U S A 2005 Mar 22;102(12):4512-7.
    pmc: PMC552973pubmed: 15753288doi: 10.1073/pnas.0408773102google scholar: lookup
  36. Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection.. J Gen Virol 2007 Jan;88(Pt 1):217-225.
    pubmed: 17170454doi: 10.1099/vir.0.81995-0google scholar: lookup
  37. Leroux C, Issel CJ, Montelaro RC. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.. J Virol 1997 Dec;71(12):9627-39.
    pmc: PMC230271pubmed: 9371627doi: 10.1128/JVI.71.12.9627-9639.1997google scholar: lookup
  38. Howe L, Leroux C, Issel CJ, Montelaro RC. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.. J Virol 2002 Nov;76(21):10588-97.
    pmc: PMC136617pubmed: 12368301doi: 10.1128/jvi.76.21.10588-10597.2002google scholar: lookup
  39. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.. Science 2010 Aug 13;329(5993):811-7.
    pmc: PMC2981354pubmed: 20616231doi: 10.1126/science.1192819google scholar: lookup
  40. Posch PE, Araujo HA, Creswell K, Praud C, Johnson AH, Hurley CK. Microvariation creates significant functional differences in the DR3 molecules.. Hum Immunol 1995 Jan;42(1):61-71.
    pubmed: 7751161doi: 10.1016/0198-8859(94)00074-zgoogle scholar: lookup
  41. Fujita Y, Otsuki H, Watanabe Y, Yasui M, Kobayashi T, Miura T, Igarashi T. Generation of a replication-competent chimeric simian-human immunodeficiency virus carrying env from subtype C clinical isolate through intracellular homologous recombination.. Virology 2013 Feb 5;436(1):100-11.
    pubmed: 23219366doi: 10.1016/j.virol.2012.10.036google scholar: lookup
  42. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, Ward BM, Bailer RT, Gottardo R, Gu W, Ferrari G, Alam SM, Denny TN, Montefiori DC, Tomaras GD, Korber BT, Nason MC, Seder RA, Koup RA, Letvin NL, Rao SS, Nabel GJ, Mascola JR. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.. Nature 2014 Jan 23;505(7484):502-8.
    pmc: PMC3946913pubmed: 24352234doi: 10.1038/nature12893google scholar: lookup
  43. Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.. Annu Rev Med 2015;66:423-37.
    pubmed: 25341006doi: 10.1146/annurev-med-052912-123749google scholar: lookup

Citations

This article has been cited 7 times.
  1. Wang XF, Zhang X, Ma W, Li J, Wang X. Host cell restriction factors of equine infectious anemia virus.. Virol Sin 2023 Aug;38(4):485-496.
    doi: 10.1016/j.virs.2023.07.001pubmed: 37419416google scholar: lookup
  2. Hu Z, Guo K, Du C, Sun J, Naletoski I, Chu X, Lin Y, Wang X, Barrandeguy M, Samuel M, Wang W, Lau PI, Wernery U, Raghavan R, Wang X. Development and evaluation of a blocking ELISA for serological diagnosis of equine infectious anemia.. Appl Microbiol Biotechnol 2023 May;107(10):3305-3317.
    doi: 10.1007/s00253-023-12504-5pubmed: 37039847google scholar: lookup
  3. Li J, Zhang X, Bai B, Zhang M, Ma W, Lin Y, Wang X, Wang XF. Identification of a Novel Post-transcriptional Transactivator from the Equine Infectious Anemia Virus.. J Virol 2022 Dec 21;96(24):e0121022.
    doi: 10.1128/jvi.01210-22pubmed: 36448796google scholar: lookup
  4. Zhang X, Li J, Zhang M, Bai B, Ma W, Lin Y, Guo X, Wang XF, Wang X. A Novel, Fully Spliced, Accessory Gene in Equine Lentivirus with Distinct Rev-Responsive Element.. J Virol 2022 Sep 28;96(18):e0098622.
    doi: 10.1128/jvi.00986-22pubmed: 36069548google scholar: lookup
  5. Wang Y, Ma G, Wang XF, Na L, Guo X, Zhang J, Liu C, Du C, Qi T, Lin Y, Wang X. Keap1 recognizes EIAV early accessory protein Rev to promote antiviral defense.. PLoS Pathog 2022 Feb;18(2):e1009986.
    doi: 10.1371/journal.ppat.1009986pubmed: 35139135google scholar: lookup
  6. Zhang Y, Pan Q, Guo R, Liu A, Xu Z, Gao Y, Cui H, Liu C, Qi X, Zhang Y, Li K, Gao L, Wang X. Immunogenicity of Novel Live Vaccine Based on an Artificial rHN20 Strain against Emerging Fowl Adenovirus 4.. Viruses 2021 Oct 26;13(11).
    doi: 10.3390/v13112153pubmed: 34834960google scholar: lookup
  7. Ren H, Yin X, Su C, Guo M, Wang XF, Na L, Lin Y, Wang X. Equine lentivirus counteracts SAMHD1 restriction by Rev-mediated degradation of SAMHD1 via the BECN1-dependent lysosomal pathway.. Autophagy 2021 Oct;17(10):2800-2817.
    doi: 10.1080/15548627.2020.1846301pubmed: 33172327google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.